Citations

Showing 10 of 108135 citations.

Things We Do for No Reason™: Emergent hemodialysis after intravascular iodinated contrast exposure in chronic hemodialysis patients
Ninan, Jacob, Reddy, Swetha , Qureshi, Fawad

Mayo Clinic

Journal of Hospital Medicine | September 24, 2021 | Volume: 17 | Issue: 8 | Pages: 653-656

10.12788/jhm.3683 | PMID 39109651 Get It

Understanding diagnostic processes in emergency departments: a mixed methods case study protocol
Daniel, Michelle , Chandanabhumma, P. Paul , Fetters, Michael D. , Canvasser, Andrew B, Singh, Hardeep , Mahajan, Prashant , Pasupathy, Kalyan, Singh, Hardeep , Park, Sun Young , Seifert, Colleen M. , Wilson, Eric A. , Pasupathy, Kalyan S.

Mayo Clinic

BMJ Open | September 24, 2021 | Volume: 11 | Issue: 9 | Pages: e044194

10.1136/bmjopen-2020-044194 | PMID 34561251 Get It

Introduction Diagnostic processes in the emergency department (ED) involve multiple interactions among individuals who interface with information systems to access and record information. A better understanding of diagnostic processes is needed to mitigate errors. This paper describes a study protocol to map diagnostic processes in the ED as a foundation for developing future error mitigation strategies. Methods and analysis This study of an adult and a paediatric academic ED uses a prospective mixed methods case study design informed by an ED-specific diagnostic decision-making model (the modified ED-National Academies of Sciences, Engineering and Medicine (NASEM) model) and two cognitive theories (dual process theory and distributed cognition). Data sources include audio recordings of patient and care team interactions, electronic health record data, observer field notes and stakeholder interviews. Multiple qualitative analysis methods will be used to explore diagnostic processes in situ, including systems information flow, human–human and human–system interactions and contextual factors influencing cognition. The study has three parts. Part 1 involves prospective field observations of patients with undifferentiated symptoms at high risk for diagnostic error, where each patient is followed throughout the entire care delivery process. Part 2 involves observing individual care team providers over a 4-hour window to capture their diagnostic workflow, team coordination and communication across multiple patients. Part 3 uses interviews with key stakeholders to understand different perspectives on the diagnostic process, as well as perceived strengths and vulnerabilities, in order to enrich the ED-NASEM diagnostic model. Ethics and dissemination The University of Michigan Institutional Review Board approved this study, HUM00156261. This foundational work will help identify strengths and vulnerabilities in diagnostic processes. Further, it will inform the future development and testing of patient, provider and systems-level interventions for mitigating error and improving patient safety in these and other EDs. The work will be disseminated through journal publications and presentations at national and international meetings.
Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation
Stecher, Chad , Everhart, Alexander , Smith, Laura Barrie , Jena, Anupam B. , Ross, Joseph S. , Desai, Nihar R. , Shah, Nilay D. , Karaca‐Mandic, Pinar , Jena, Anupam B , Shah, Nilay , Ross, Joseph S , Everhart, Alexander O

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 24, 2021 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/circoutcomes.121.008040 | PMID 34555928 Get It

Background: Physicians’ professional networks are an important source of new medical information and have been shown to influence the adoption of new treatments, but it is unknown how physician networks impact the de-adoption of harmful practices. Methods: We analyzed changes in physicians’ use of dronedarone after the PALLAS trial (Palbociclib Collaborative Adjuvant Study; November 2011) showed that dronedarone increased the risk of death from cardiovascular events among patients with permanent atrial fibrillation. Deidentified administrative claims from the OptumLabs Data Warehouse were combined with physicians’ demographic information from the Doximity database and publicly available data on physicians’ patient-sharing relationships compiled by the Centers for Medicare and Medicaid Services. We used a linear probability model with an interrupted linear time trend specification to model the impact of the PALLAS trial on physicians’ dronedarone usage between 2009 and 2014. Results: Before the PALLAS trial, the use of dronedarone was increasing by 0.22 percentage points per quarter (95% CI, 0.19–0.25) in our Medicare Advantage sample (N=343 429 patient-quarter observations) and 0.63 percentage points per quarter (95% CI, 0.52–0.75) in our commercially insured sample (N=44 402 patient-quarter observations). After the PALLAS trial and subsequent United States Food and Drug Administration black box warning, physicians in the Medicare Advantage sample with an above-median number of network connections to other physicians decreased their quarterly usage of dronedarone by 0.12 percentage points more per quarter (95% CI, −0.20 to −0.04; P =0.031) than physicians with equal to or below the median number of network connections. Similar patterns existed in the commercially insured sample ( P =0.0318). Conclusions: After controlling for a wide range of patient, physician, and geographic characteristics, physicians with a greater number of network connections were faster de-adopters of dronedarone for patients with permanent atrial fibrillation after the PALLAS trial and subsequent United States Food and Drug Administration black box warning detailed the harmfulness of dronedarone for these patients. Policies for improving physicians’ responsiveness to new medical information should consider utilizing the influence of these important professional network relationships.
Piperacillin–Tazobactam-Induced Immune Thrombocytopenia: A Case Report
Kiliaki, Shangwe A. , Kiliaki, Shangwe

Mayo Clinic

Journal of Pharmacy Practice | September 24, 2021 | Volume: 36 | Issue: 2 | Pages: 451-452

10.1177/08971900211048140 | PMID 34558345 Get It

Drug-induced immune thrombocytopenia is an isolated thrombocytopenia caused by accelerated platelet destruction from drug-dependent, platelet-reactive antibodies. Heparin-induced thrombocytopenia is the most common drug-induced immune thrombocytopenia. Common implicated antibiotics for drug-induced immune thrombocytopenia include ceftriaxone, trimethoprim–sulfamethoxazole, vancomycin, and penicillin. The platelet nadir can be less than 20 × 10 (9)/L and typically occurs within 1 to 2 weeks of exposure to the inciting drug. Although rare, drug-induced immune thrombocytopenia can be fatal. Diagnosis is made by excluding other causes of thrombocytopenia. Laboratory testing for drug-dependent antiplatelet antibodies is often helpful but not required. Thrombocytopenia typically improves within 1 to 2 days of drug discontinuation and platelet count returns to normal within a week. Identifying and discontinuing the implicated medication is key to prevention of serious complications. A patient case of drug-induced immune thrombocytopenia is described after initiation of empiric piperacillin–tazobactam for refractory right foot cellulitis in the setting of right fourth toe diabetic ulcer.
Outcomes of Elderly Patients Undergoing Left Atrial Appendage Closure
Sanjoy, Shubrandu , Choi, Yun‐Hee , Sparrow, Robert T. , Jneid, Hani , Nombela‐Franco, Luis , Azzalini, Lorenzo , Holmes, David R. , Elgendy, Islam Y. , Mamas, Mamas A. , Sanjoy, Shubrandu S , Nombela-Franco, Luis , Azzalini, Lorenzo , Holmes, David R , Elgendy, Islam Y , Baranchuk, Adrian , Mamas, Mamas , Bagur, Rodrigo , Abbott, J. Dawn , Alraies, M Chadi , Baranchuk, Adrián , Bagur, Rodrigo

Mayo Clinic

Journal of the American Heart Association | September 24, 2021 | Volume: 10 | Issue: 19 | Pages: No page available

10.1161/jaha.121.021973 | PMID 34558289 Get It

Background Elderly patients have a higher burden of comorbidities that influence clinical outcomes. We aimed to compare in‐hospital outcomes in patients ≥80 years old to younger patients, and to determine the factors associated with increased risk of major adverse events (MAE) after left atrial appendage closure. Methods and Results The National Inpatient Sample was used to identify discharges after left atrial appendage closure between October 2015 and December 2018. The primary outcome was in‐hospital MAE defined as the composite of postprocedural bleeding, vascular and cardiac complications, acute kidney injury, stroke, and death. A total of 6779 hospitalizations were identified, of which, 2371 (35%) were ≥80 years old and 4408 (65%) were <80 years old. Patients ≥80 years old experienced a higher rate of MAE compared with those aged <80 years old (6.0% versus 4.6%, P =0.01), and this difference was driven by a numerically higher rate of cardiac complications (2.4% versus 1.8%, P =0.09) and death (0.3% versus 0.1%, P =0.05) among individuals ≥80 years old. In patients ≥80 years old, higher odds of in‐hospital MAE were observed in women (1.61‐fold), and those with preprocedural congestive heart failure (≈2‐fold), diabetes (≈1.5‐fold), renal disease (≈2.6‐fold), anemia (≈2.7‐fold), and dementia (≈5‐fold). In patients <80 years old, a higher risk of in‐hospital MAE was encountered among women (≈1.4‐fold) and those with diabetes (≈1.3‐fold), renal disease (≈2.6‐fold), anemia (≈2‐fold), and dyslipidemia (≈1.2‐fold). Conclusions Patients ≥80 years old had higher rates of in‐hospital MAE compared with patients aged <80 years old. Female sex and the presence of heart failure, diabetes, renal disease, and anemia were factors associated with in‐hospital MAE among both groups.
A consensus statement on the use of botulinum toxin in pediatric patients
Vova, Joshua , Green, Michael , Brandenburg, Joline E. , Davidson, Loren , Paulson, Andrea, Deshpande, Supreet , Inanoglu, Didem, Vova, Joshua A , Oleszek, Joyce L. , McLaughlin, Matthew J.

Mayo Clinic

PM&R | September 24, 2021 | Volume: 14 | Issue: 9 | Pages: 1116-1142

10.1002/pmrj.12713 | PMID 34558213 Get It

AbstractBotulinum toxin has been used in medicine for the past 30 years. However, there continues to be controversy about the appropriate uses and dosing, especially in the pediatric population. A panel of nine pediatric physiatrists from different regions and previous training programs in the United States were nominated based on institutional reputation and botulinum toxin (BoNT) experience. Based on a review of the current literature, the goal was to provide the rationale for recommendations on the administration of BoNT in the pediatric population. The goal was not only to review safety, dosing, and injection techniques but also to develop a consensus on the appropriate uses in the pediatric population. In addition to upper and lower limb spasticity, the consensus also provides recommendations for congenital muscular torticollis, cervical dystonia, sialorrhea, and brachial plexus palsies.
Radiomics Derived Brain Age Predicts Functional Outcome After Acute Ischemic Stroke
Bretzner, Martin , Bonkhoff, Anna K. , Schirmer, Markus D. , Hong, Sung‐Min , Donahue, Kathleen, Etherton, Mark R. , Rist, Pamela M. , Nardin, Marco, Regenhardt, Robert W. , Leclerc, X. , Gautherot, Morgan , Wang, Clinton, Benavente, Oscar, Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , McArdle, Patrick, Rolfs, Arndt , Schmidt, Reinhold, Sharma, Pankaj , Słowik, Agnieszka , Sousa, Alessandro Viana Oliveira e, Strbian, Daniel , Wassélius, Johan , Woo, Daniel , Worrall, Bradford B. , Maguire, Jane , Golland, Polina , Kuchcinski, Grégory , Rost, Natalia S. , Bretzner, Martin , Strbian, Daniel , Regenhardt, Robert W , Dalca, Adrian Vasile , Giese, Anne‐Katrin , Lopes, Renaud , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Jood, Katarina , Lemmens, Robin , Levi, Christopher , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Sousa, Alessandro Augusto Viana Oliveira e, Stanne, Tara M. , Tatlisumak, Turgut , Thijs, Vincent , Vagal, Achala , Wu, Ona , Zand, Ramin , Lindgren, Arne G. , Jern, Christina

Mayo Clinic

No container title available | September 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-923769/v1 Get It

Abstract While chronological age is one of the most influential determinants of post-stroke outcomes, little is known of the impact of neuroimaging-derived biological brain age. We here first examine whether radiomics analysis of the texture of brain T2-FLAIR MRI images can be used to predict brain age in stroke patients. We then assess the clinical determinants of accelerated brain aging and, finally, its impact on post-stroke functional outcomes. Leveraging a multisite cohort of 4,163 ischemic stroke patients, we show that older-appearing patients have more hypertension, diabetes mellitus, prior strokes, and smoking history and are more likely to develop worse post-stroke outcomes than their younger-appearing counterparts. Our results strengthen the importance of preventive medicine for maintaining brain health in stroke patients as they age and suggest a novel methodology to capture previously undescribed prognostic information available on commonly acquired MRI sequences during routine stroke care.
Beyond the Belmont Report
Siddiqui, Wamia , Sharp, Richard R. , Sharp, Richard R

Mayo Clinic

The American Journal of Bioethics | September 23, 2021 | Volume: 21 | Issue: 10 | Pages: 1-4

10.1080/15265161.2021.1972649 | PMID 34554060 Get It

Chickens & Eggs, Pigs and Their Lipstick: The Trouble with Asking Principlism to Do Too Much
Tilburt, Jon C.

Mayo Clinic

The American Journal of Bioethics | September 23, 2021 | Volume: 21 | Issue: 10 | Pages: 13-14

10.1080/15265161.2021.1965246 | PMID 34554072 Get It